HEMOVENT
4.10.2021 18:14:12 CEST | Business Wire | Press release
MicroPort Scientific Corporation (hereinafter referred to as “MicroPort®”) announced on October 4th , 2021, through its critical care subsidiary, MicroPort Surgical B.V. (“MicroPort® Surgery”), has acquired 100% of the equity held by existing shareholders of Hemovent GmbH (hereinafter referred to as “Hemovent”) for a total cash consideration of up to €123 million. Upon completion of the acquisition, Hemovent will become a wholly owned subsidiary of MicroPort®.
Hemovent , established in 2013 in Aachen, Germany, is a medical device company specializing in the development of ground-breaking Extracorporeal Life Support (ECLS) systems. Hemovent’s flagship product, the MOBYBOX® system, is the first fully integrated ECLS system to manage both perfusion and gas exchange in a single device, and has set a new standard for ECMO devices in terms of mobility and ease of use.
MicroPort® has established its foothold in the critical care sector with its subsidiary MicroPort® Surgery, which is committed to providing patients with comprehensive medical solutions for cardiac surgery, emergency and critical care. The Hemovent acquisition will further MicroPort®’s strategy in emergency and critical care, through the combination of Cardiopulmonary Bypass (CPB) with the R&D, manufacturing and commercialization of ECMO products.
Mr. Zhiguang Cheng , Senior Vice President of MicroPort® Surgery, said, “Relying on years of expertise accumulated in cardiac systemic circulation, MicroPort® Surgery has been actively expanding its product portfolio into the intensive care field. The light, portable and easy to operate features of MOBYBOX® enable us to expand the application of this innovative ECMO technology to better meet the medical needs in the post-pandemic era. After the completion of the acquisition, MicroPort® Surgery will pursue device internationalization through a US FDA filing and the clinical registration of MOBYBOX® in China.”
Mr. Christof Lenz , CEO of Hemovent, added, “We are extremely happy with our new partner MicroPort® who can leverage Hemovent’s team efforts with its profound resources, industry expertise and global reach in order to raise our unique technology to the next level. We are looking forward to a significant scale up of business activities in our current Aachen facility, as well as growing our international operations and distribution chains. We trust in our MOBYBOX® system to be an eventual game changer for the application of ECLS, as it offers unrivalled mobility and ease of use in this area of critical care.”
To date Hemovent has been backed by a consortium of institutional investors led by MIG Capital .
William Blair acted as exclusive financial advisor, and LUTZ | ABEL acted as exclusive legal advisor to Hemovent’s shareholders. TRENZ Attorneys acted as exclusive legal advisor to Hemovent. Freshfields Bruckhaus Deringer acted as exclusive legal advisor to Microport®.
The transaction has received all the necessary and customary regulatory approvals. Completion of the transaction is expected in Q4/2021.
CAUTION: The Hemovent MOBYBOX System is not approved for distribution or sale outside of the EU.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005757/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amadeus Explores Next-Generation Flight Search with NVIDIA21.10.2026 14:00:00 CEST | Press release
Amadeus and NVIDIA have been collaborating to explore how accelerated computing and travel-specific AI could support faster, more scalable and more efficient flight search. Building on this work, the companies have now signed a Memorandum of Understanding (MoU) to deepen their collaboration and accelerate further exploration. As AI assistants increasingly search on behalf of travelers, they are changing both the volume and complexity of demand placed on travel technology. Amadeus, in collaboration with NVIDIA, have already conducted initial technical assessments and benchmarking activities, on the NVIDIA Hopper and Blackwell platform, NVIDIA's accelerated computing architectures designed for AI and high-performance computing workloads, to better understand how accelerated computing could support large-scale travel shopping workloads. Through the MoU, Amadeus and NVIDIA will continue this collaboration, with aims to deliver faster, more scalable and more efficient flight search as AI-po
TreviPay Expands Pay by Invoice Availability for Walmart Business Customers21.10.2026 14:00:00 CEST | Press release
The general availability gives eligible organizations more flexibility with net 30-day terms, a dedicated business line of credit and streamlined reconciliation TreviPay, a global B2B payments infrastructure partner, today announced the general availability of Pay By Invoice for eligible Walmart Business customers. Following an initial pilot, the expanded availability gives more organizations a new way to manage purchasing and payments online and in Walmart stores. Walmart Business Pay By Invoice provides net 30-day terms, a dedicated business line of credit and detailed invoicing built into the Walmart Business purchasing experience. Powered by TreviPay, Walmart Business Pay By Invoice is designed to give organizations greater flexibility in how they manage business purchases and payments. Eligible customers can get what they need and pay on net 30-day terms, helping them preserve cash flow for other priorities while keeping operations moving. Purchasing controls and payment reconcili
Global Network for the Advancement of Metabolic Psychiatry (MetPsy) Launches with $20 Million Investment in Clinical Care, Education and Research at McLean Hospital21.10.2026 14:00:00 CEST | Press release
Baszucki Group funding awarded to McLean Hospital to establish a flagship clinical and research center, and jointly to McLean and MH² for medical education and training initiatives Baszucki Group today announced the launch of the Global Network for the Advancement of Metabolic Psychiatry (MetPsy), uniting researchers and clinicians worldwide to advance evidence-based practice in metabolic psychiatry through clinical care, education, and research. The launch is accompanied by a new $20 million grant from Baszucki Group to build a clinical and research center at McLean Hospital, a member of Mass General Brigham, creating the infrastructure to deliver metabolic approaches to psychiatric care at scale. The grant also supports medical education and training initiatives co-led by MH², a clinical practice, training and education hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021217733/en/ MetPsy, a global network for metabo
Starburst Introduces Starburst Torin, a GPU-Native Analytics Engine Built on NVIDIA cuDF21.10.2026 13:30:00 CEST | Press release
Starburst Torin runs SQL natively on NVIDIA GPUs, delivering up to 7x faster query performance to accelerate AI agents and enable data teams to run more workloads without moving data or changing existing SQL or applications. Starburst today announced limited general availability of Starburst Torin, a GPU-native, Trino-based analytics engine for Starburst Enterprise. Built on NVIDIA cuDF, Torin accelerates SQL workloads with native GPU execution, delivering up to 7x faster query performance.1 By complementing Starburst’s existing CPU engine, Torin gives enterprises the flexibility to run workloads on CPUs or GPUs without changing existing Trino SQL queries, applications, or agents. AI agents create a different kind of load on data platforms. A single agent task can trigger a chain of dependent queries, where delays in one query can slow the entire workflow. These bottlenecks also affect interactive analytics, making it harder to explore data, evaluate results, and make decisions in real
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 202621.10.2026 12:47:00 CEST | Press release
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, the company shared research highlighting the importance of assay conditions in evaluating complement activity and the effects of complement-targeting therapies. Unlike conventional assays that often use highly diluted serum, CIMED assays use 50% serum. Research presented by Compvide at EMCHD highlighted how serum dilution can influence measurements of complement inhibition, particularly at lower drug concentrations. These findings underscore the importance of assay conditions when evaluating pote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom